A Study to Evaluate the Safety of K-755 in Healthy Volunteers

Kowa Company, Ltd.121 enrolled

Overview

This is a Phase 1 study designed to explore the safety, tolerability and pharmacokinetics of K-755 following oral administration to healthy male and female volunteers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Enrollment

121

Conditions

Healthy

Interventions

K-755 Part A (SAD)DRUG

Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.

Placebo Part A (SAD)DRUG

Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.

K-755 Part B (MAD)DRUG

Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Able to comprehend and willing to sign an ICF and to abide by the study restrictions. 2. Males or females, of any race, between 18 and 45 years of age. 3. Body mass index (BMI) between 18.0 and 28.0 kg/m2. 4. Hematology, clinical chemistry, and urinalysis test results within the reference ranges or showing no clinically relevant deviations, as judged by the Investigator. 5. No clinically significant abnormalities on the basis of medical history, physical examination findings, and vital signs. 6. All females must have a negative serum pregnancy test. 7. Able and willing to comply with the protocol and study procedures. Exclusion Criteria: 1. Female subject who are pregnant or breastfeeding. 2. Subject with presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment. 3. Subject with any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of K-755. 4. Subject with presence of an active malignancy or within the past 5 years a malignancy of any type, other than basal cell carcinoma of the skin. 5. Subject has a history of type 1 hypersensitivity to any medication and/or clinically relevant food allergies. 6. Subject has a history of drug addiction. 7. Subject has a positive screen for drugs of abuse, cotinine or alcohol. 8. Subject has a history of regular alcohol consumption within 6 months of the study. 9. Subject has smoked tobacco within 6 months prior to Check-in, or has used non-inhaled tobacco- or nicotine-containing products within 3 months prior to Check-in. 10. Subject has used prescription or over-the-counter medications, dietary/nutritional supplements (except paracetamol or vitamin supplements) 11. Subject has used steroid medications (oral, inhaled, parenteral, or topical) within 30 days or 5 half-lives (whichever is longer) before study drug administration. 12. Subject has participated in an investigational drug study within 30 days or 5 half-lives (whichever is longer) before study drug administration. 13. Subject has a positive screen for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 and 2 antigens/antibodies. 14. Subject has had a clinically significant acute illness within 4 weeks or other illness within 5 days before the first study drug administration. 15. Subject or a family member of the subject is a member of the professional or ancillary personnel working at the investigative site involved in the study. 16. Not suitable for entry into the study in the opinion of the Investigator. 17. Receipt of blood products within 2 months prior to Check-in.

Locations (1)

CMAX, Clinical Research Pty Ltd

Adelaide, South Australia, Australia

Outcomes

Primary Outcomes

Part A, B, C, D and E: Incidence and severity of Adverse Events

A treatment-emergent adverse events (TEAE) will be summarized by treatment and overall, and summarized for each treatment by severity and relationship to study drug. All TEAEs leading to withdrawal, or SAEs, will be summarized.

Time frame: Up to 28 days after last administration

Part A, B, C, D and E: Number of subjects with clinical laboratory test abnormalities

The clinical laboratory will include hematology (hematocrit, hemoglobin, mean cell hemoglobin, mean cell hemoglobin concentration, mean cell volume, platelet count, red blood cell count, white blood cell count), clinical chemistry (alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, calcium, chloride, cholesterol, creatinine, creatine phosphokinase, direct bilirubin, estimated glomerular filtration rate, gamma glutamyl transferase, glucose. inorganic phosphate, iron, lactate dehydrogenase, phosphorus, potassium, sodium, total bilirubin, total CO2, total protein, triglyceride, urea, uric acid), and urinalysis (bilirubin, blood, color and appearance, glucose, ketones, leukocyte esterase, nitrite, pH, protein, specific gravity, urobilinogen, microscopic examination, electrolytes). Abnormality will be determined by the investigator.

Time frame: Up to 28 days after last administration

Part A, B, C, D and E: Number of subjects with vital signs abnormalities

The vital sign will include blood pressure (mmHg), pulse rate (bpm), respiratory rate (breaths/min), and body temperature (degree Celsius). Abnormality will be determined by the investigator.

Time frame: Up to 28 days after last administration

Part A, B, C, D and E: Number of subjects with clinically significant change in body weight

Change in body weight (kg) at baseline and post dose will be measured. Clinical significance will be determined by the investigator.

Time frame: Up to 28 days after last administration

Part A, B, C, D and E: Number of subjects with abnormal findings in physical examinations

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Part A: AUC0-inf of K-755

Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity

Time frame: Up to 28 days after single administration

Part A: AUC0-tlast of K-755

AUC from time zero to the time of the last measurable concentration

Time frame: Up to 28 days after single administration

Part A: Cmax of K-755

Maximum plasma concentration

Time frame: Up to 28 days after single administration

Part A: Tmax of K-755

Time of the observed maximum plasma concentration

Time frame: Up to 28 days after single administration

Part A: t1/2 of K-755

Terminal plasma elimination half-life

Time frame: Up to 28 days after single administration

Part B: AUC0-τ of K-755

AUC over the dosing interval

Time frame: Up to 28 days after repeated administration

Part B: Cmax of K-755

Maximum plasma concentration

Time frame: Up to 28 days after repeated administration

Part B: Tmax of K-755

Time of the observed maximum plasma concentration

Time frame: Up to 28 days after repeated administration

Part B: t1/2 of K-755

Terminal plasma elimination half-life

Time frame: Up to 28 days after repeated administration

Part C: AUC0-inf of K-755

Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity